Resources 
    • About Us 

    • Home Report Store Rapid Diagnostics Market
    Rapid Diagnostics Market

    Rapid Diagnostics Market Size, Share, Forecast, & Trends Analysis by Product (Kits [OTC, Professional], Readers) Platform (Lateral Flow, Serological, PCR) Application (Diabetes, Infectious Diseases, Pregnancy, HIV) Sample (Blood) - Global Forecast to 2031

    Report ID:MRHC - 104553 Pages: 260 Sep-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 Hours

    The Rapid Diagnostics Market was valued at $14.74 billion in 2023. This market is expected to reach $22.65 billion by 2031 from an estimated $14.57 billion in 2024, at a CAGR of 6.5% during the forecast period from 2024 to 2031.

    Rapid Diagnostics Market Size & Forecast

    RDT kits are extensively utilized in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens, antibodies, and genetic material or proteins related to particular health conditions or diseases. These kits help uncover the underlying mechanisms of disease and empower doctors and healthcare professionals to make critical medical decisions.

    The rapid growth of the rapid diagnostics market is driven by several key factors, including the increasing demand for point-of-care (POC) diagnostics, the rising prevalence of chronic diseases alongside an aging population, the need for swift decision-making in emergency departments, and ongoing technological innovations.

    Rapid Diagnostics Market Growth Drivers

    Rising Prevalence of Infectious Diseases

    The exponential growth of the human population has resulted in the expansion of human settlements into new geographical areas, increasing the likelihood of contact with animals that may serve as potential hosts for infectious disease agents. This phenomenon has contributed to the emergence of various infectious diseases throughout history. Additionally, there is a rising prevalence of infectious diseases on a global scale. For example, a July 2022 article in the United Nations’ Africa Renewal digital magazine highlighted that the risk of outbreaks caused by zoonotic pathogens, such as the Ebola and monkeypox viruses, is increasing. According to the WHO, there has been a 63% rise in zoonotic disease outbreaks in Africa from 2012 to 2022 compared to the period from 2001 to 2011.

    • In September 2023, the Ministry of Health and Family Welfare of India reported six confirmed cases of the Nipah virus in the state of Kerala. As of September 27, 2024, 1,288 contact cases related to the Nipah virus have been reported.
    • The global epidemiological burden of sepsis has risen significantly in recent years. According to the WHO, sepsis is estimated to affect over 30 million people worldwide, resulting in approximately 6 million deaths annually.
    • In 2021, approximately 38.4 million people were living with HIV, including 1.7 million children. Of this total, 20.6 million (53%) resided in eastern and southern Africa, 5 million (13%) in western and central Africa, 6 million (15%) in Asia and the Pacific, and 2.3 million (5%) in Western and Central Europe and North America.

    Rapid diagnostic tests enable the early detection of infectious diseases, which is valuable for controlling their spread. The rising prevalence and outbreaks of infectious diseases are expected to drive the market's growth.

    Increasing Need for Rapid Decision-making

    Emergency departments in hospitals play a vital role in delivering both inpatient and outpatient services, essential for preventing death or serious health impairment. However, overcrowding in these departments is a well-documented challenge, driven by factors such as the increasing geriatric population and referrals from primary care. To address this issue, rapid diagnostics are being increasingly adopted in emergency departments to improve clinical decision-making related to patient diagnosis, treatment, monitoring, and prognosis. This approach also aims to optimize resource utilization and alleviate overcrowding. The rising number of patient admissions in emergency departments globally further fuels the demand for rapid diagnostic kits.

    Rapid Diagnostics Market Trends

    Lateral Flow Assays Containing DNA Nanostructures

    A lateral flow assay is a rapid diagnostic test designed to confirm the presence or absence of target analytes, such as pathogens or biomarkers, in human samples like blood, serum, urine, or saliva. These assays utilize antibodies on a conjugate pad that bind to the target antigen to generate results. Traditional antibodies can be substituted with DNA nanostructures that offer high binding affinity and specificity for the target antigen. For instance, Atom Bioworks Inc. (U.S.) has developed the DNA Star Rapid Diagnostics Platform, a lateral flow assay kit that incorporates nanoengineered DNA nanostructures instead of conventional antibodies. In 2021, the company received the Rapid Testing Innovation Award at the Advanced Lateral Flow Conference organized by DCN Diagnostics (U.S.) and DIALUNOX GmbH (Germany).

    Smartphone-based Detection Platforms

    The demand for high-quality medical services continues to rise. Technological advancements, such as portable devices for use at home or in remote areas, significantly enhance both the quantity and quality of medical care. Smartphone-based platforms are increasingly applied in tele-imaging, food technology, and education, demonstrating their versatility across various medical applications. Rapid diagnostics are crucial for screening patients in any healthcare setting. Given the high costs of diagnosis and the limited availability of benchtop readers in resource-constrained areas, the demand for smartphone-based rapid diagnostics is steadily increasing.

    Many companies in the rapid diagnostics market are developing smartphone-based, end-to-end platforms that integrate with mobile applications to streamline test result generation in point-of-care environments. These platforms often incorporate deep learning methods to improve device efficiency. Additionally, smartphone-based detection methods facilitate automated result detection and analysis while supporting human expertise. Patient data transactions are secured and validated through blockchain technology, ensuring trust and security in data handling.

    Rapid Diagnostics Market Opportunity

    Emerging Markets

    Emerging economies worldwide are driving demand for healthcare services and treatments due to rapid urbanization, improving healthcare infrastructure and expenditures, expanding health insurance coverage, rising disposable incomes, and a growing prevalence of both non-communicable and infectious diseases.

    According to the International Diabetes Federation, in 2021, the number of individuals with diabetes in middle-income countries—including China, Brazil, Bangladesh, India, and Indonesia—was 414 million. This figure is projected to rise to 623.3 million by 2045. Additionally, the World Health Organization reported in May 2022 that, in low- and middle-income countries, 15 out of every 100 patients in acute-care hospitals acquire at least one healthcare-associated infection (HAI) during their hospital stay, with one out of ten of these infections leading to mortality.

    Rapid Diagnostics Market Study: Key Findings

    The Kits Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024

    Based on product, the rapid diagnostics market is segmented into kits and equipment. In 2024, the kits segment is expected to account for the largest share of 67.6% of the rapid diagnostics market. The significant share of this segment can be attributed to the increasing adoption and frequent use of kits. Additionally, the expanding portfolio of disease-specific rapid kits for the early diagnosis of chronic and infectious diseases, along with ongoing technological advancements, further supports the segment's substantial market share. Moreover, this segment is expected to register the highest CAGR of 7.2% during the forecast period.

    The Immunoassay Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024

    Based on platform, the rapid diagnostics market is segmented into immunoassays, molecular detection tests, and other rapid diagnostic platforms. In 2024, the immunoassay segment is expected to account for the largest share of 54.2% of the rapid diagnostics market. The substantial share of this segment can be attributed to the high prevalence of infectious and chronic diseases, the lower costs of rapid immunoassay tests compared to traditional laboratory-based tests, ongoing technological innovations, and the increasing demand for lateral flow assay kits suitable for home use.

    However, the molecular detection tests segment is expected to register the highest CAGR of 6.2% during the forecast period. The factors driving the segment growth are the high sensitivity and accuracy of these tests, the growing need for advanced diagnostic techniques, and the widening applications of molecular detection tests in various fields.

    The Infectious Disease Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024

    Based on application, the rapid diagnostics market is segmented into blood glucose testing, cardiac metabolism testing, infectious diseases testing, pregnancy & fertility testing, hematology testing, tumor/cancer markers testing, urinalysis, cholesterol testing, and other tests. In 2024, the infectious disease segment is expected to account for the largest share of the rapid diagnostics market. The large share of this segment is mainly attributed to the rising prevalence of infectious diseases, high awareness, and major efforts regarding early diagnosis, monitoring, and surveillance of infectious diseases after the COVID-19 pandemic.

    However, the tumor/cancer markers testing segment is expected to register the highest CAGR during the forecast period. The factors attributed to this segment’s growth are the rising prevalence of cancer worldwide, growing investments and funding for cancer biomarker research, and advancements in cancer diagnostic technologies.

    The Blood Segment to Account for the Largest Share of the Rapid Diagnostics Market in 2024

    Based on sample type, the rapid diagnostics market is segmented into blood, saliva, nasal, and oropharyngeal, urine, and other samples. In 2024, the blood segment is expected to account for the largest share of the market. The large share of this segment is attributed to the high availability of rapid tests requiring blood as the sample, the high tendency of the blood samples to retain the genetic material intact without altering its properties compared to other samples, and easy extraction and storage options for blood samples.

    Moreover, the blood segment is expected to register the highest CAGR during the forecast period due to players' growing focus on launching rapid tests that require blood samples.

    The Hospitals & Clinics Segment to Account for the largest share of the Rapid Diagnostics Market in 2024

    Based on end user, the rapid diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, home care/self-testing, and other end users. In 2024, the hospitals & clinics segment is estimated to account for the largest share of the rapid diagnostics market. The large share of this segment is mainly attributed to the increasing number of patient visits to hospitals for various healthcare services, such as diagnosis, treatments, and surgeries with well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, the ease of accessibility, and better health coverage for hospital-based healthcare services from various private and group insurance plans.

    However, the home care/self-testing segment is expected to register the highest CAGR during the forecast period. The rising incidence of chronic diseases necessitating ongoing care and regular monitoring, coupled with the expanding utilization of home healthcare services and the enhanced availability of accessible and advanced point-of-care diagnostic products, are key drivers fueling the demand for rapid diagnostics in home environments.

    Geographical Analysis

    Based on geography, the rapid diagnostics market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2024, North America is expected to account for the largest share of 41% of the rapid diagnostics market. The large share of North America is attributed to the region’s highly developed diagnostic infrastructure, the high number of laboratory tests performed annually, the rising prevalence of chronic diseases coupled with growth in the aging population, the rising number of inpatient admissions, increasing awareness, and the growing adoption of self-testing kits among the general population.

    However, Asia-Pacific is expected to be the fastest-growing regional market, registering a CAGR of 10.1% during the forecast period. The aging population, the rising prevalence of infectious and chronic diseases, and various government initiatives to promote health awareness drive the rapid diagnostics market in Asia-Pacific.

    Rapid Diagnostics Market: Key Companies

    The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants in the last three to four years. The key players profiled in the rapid diagnostics market report include Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland).

    Rapid Diagnostics Market Industry Overview: Latest Developments from Key Industry Players

    • In February 2024, Bio-Rad Laboratories Inc. (U.S.) launched the Vericheck ddPCR Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. These provide rapid results for absolute quantification of replication-competent lentivirus (RCL) and replication-competent adeno-associated virus.
    • In March 2023, Abbott Laboratories (U.S.) received approval from the U.S. FDA for the company’s new traumatic brain injury (TBI) blood test.
    • In February 2023, Beckton, Dickinson, and Company (U.S.) received emergency use approval from the U.S. FDA for its new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV).

    Rapid Diagnostics Market Research Summary

    Particular

    Details

    No of Pages

    260

    Format

    PDF

    Forecast Period

    2024-2031

    Base Year

    2023

    CAGR

    6.5%

    Market Size (Value)

    $22.65 Billion by 2031

    Segments Covered

    By Product                   

    • Kits
      • OTC Kits
      • Professional Kits
    • Test Readers/Analyzers

    By Platform

    • Immunoassays
      • Lateral Flow Assays
      • Serological Assays
      • Other Immunoassays
        (Note: Other Immunoassays include flow-through immunoassays and agglutination assays)
    • Molecular Detection
      • RT-PCR
      • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Other Rapid Diagnostic Platforms
      (Note 1: Other Immunoassays include flow-through immunoassays and agglutination assays)
      (Note 2: Other rapid diagnostic platforms mainly include coagulation tests, glucose monitoring systems, dipsticks, and other rapid diagnostic platforms)

    By Application

    • Blood Glucose Testing
    • Cardiac Metabolism Testing
    • Infectious Diseases Testing
      • Influenza Testing
      • COVID-19 testing
      • HIV Testing
      • Hepatitis Testing
        • Hepatitis B
        • Hepatitis C
      • Sexually Transmitted Diseases (STD) Testing
      • Healthcare Associated Infection (HAI) Testing
      • Respiratory Disease Testing
      • Tropical Disease Testing
      • Other Infectious Disease Testing
      • (Note: Other infectious disease testing includes meningitis, norovirus [stomach flu], hand, foot, and mouth disease [HFMD], and pertussis)
    • Coagulation Testing
    • Pregnancy And Fertility Testing
    • Cardiac Metabolism Testing
    • Hematology Testing
    • Tumor/Cancer Markers Testing
    • Urinalysis
    • Cholesterol Testing
    • Other Tests
      (Note: Other tests include drugs of abuse, fecal occult, and coagulation tests)

    by Sample Type

    • Blood
    • Saliva, Nasal and Oropharyngeal
    • Urine
    • Other Sample Types
      (Note: Other Sample Types include ambulatory care centers, nursing homes, and public places (airports, hotels, and workplaces)

    End User

    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Home Care/Self Testing
    • Other End Users
      (Note: Other End Users include ambulatory care centers, nursing homes, and public places (airports, hotels, and workplaces)

    Countries Covered

    North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Switzerland, Sweden, Netherlands, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa (Saudi Arabia, South Africa, and Rest of Middle East & Africa)

    Key Companies

    Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland)

    Key questions answered in the Rapid Diagnostics Market report:

    The rapid diagnostics market covers the market sizes & forecasts for the various rapid diagnostic kits used for blood glucose testing, cardiac metabolism testing, infectious diseases testing, coagulation testing, pregnancy & fertility testing, fecal occult testing, hematology testing, tumor/cancer markers testing, drugs of abuse testing, urinalysis, and cholesterol testing. The rapid diagnostics market studied in this report involves the value analysis of various segments and subsegments of rapid diagnostic kit producers at the regional and country levels.

    The rapid diagnostics market is projected to reach $22.65 billion by 2031, at a CAGR of 6.5% during the forecast period.

    Based on product, the kits segment is estimated to account for the largest share of the rapid diagnostics market in 2024. This segment's large share is attributed to its rising adoption and repetitive kit usage. In addition, the growing portfolio of disease-specific kits for the early diagnosis of chronic diseases and the increasing technological advancements are other factors supporting its growth.

    The hospitals and clinics segment is estimated to register the fastest CAGR during the forecast period due to the increasing number of patient visits to hospitals for various healthcare services, the presence of highly skilled healthcare professionals, the ease of accessibility, and better health coverage for hospital-based healthcare services from various private and group insurance plans.

    The growing demand for POC diagnostics, emerging technological innovations, the growing prevalence of infectious diseases, the rising prevalence of chronic diseases coupled with the increasing aging population, and the growing necessity for rapid decision-making in emergency departments are the key factors driving the growth of the rapid diagnostics market. Furthermore, the growing market potential in emerging economies, such as China and India, provides significant opportunities for existing market players and new entrants in this market.

    The key players operating in the rapid diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland).

    Emerging economies from Asia, such as China and India, are projected to offer significant growth opportunities for companies operating in this market. Additionally, the rising number of people suffering from non-communicable and infectious diseases, the growing population, and rising urbanization are factors expected to offer significant growth opportunities in this region.

    Enquire
    Check Discount
    Related Tag: Rapid Diagnostics Market In vitro Diagnostic Immunoassays PCR Blood Glucose Testing Infectious Diseases Healthcare Associated Infection Pregnancy Testing Hematology Test Cancer Markers Drugs of Abuse Cholesterol Testing Rapid PCR Tests
    In Vitro Diagnostics
    Healthcare

    1.    Overview
           1.1.    Market Definition & Scope
           1.2.    Market Ecosystem
           1.3.    Currency and Limitations
           1.4.    Key Stakeholders
    2.    Research Methodology
           2.1.    Research Approach
           2.2.    Process of Data Collection & Validation
                     2.2.1.    Secondary Research
                     2.2.2.    Primary Research/Interviews with Key Opinion Leaders from the Industry
           2.3.    Market Sizing and Forecast
                     2.3.1.    Market Size Estimation Approach
                     2.3.2.    Growth Forecast Approach
                     2.3.3.    Market Share Analysis
           2.4.    Assumptions For the Study
    3.    Executive Summary
    4.    Market Insights
           4.1.    Overview
           4.2.    Drivers
                     4.2.1.    Rising Prevalence of Chronic Diseases Coupled with the Increasing Geriatric Population
                     4.2.2.    Growing Prevalence of Infectious Diseases
                     4.2.3.    Increasing Need for Rapid Decision-making
                     4.2.4.    Growing Demand for Point-of-Care (POC) Diagnostics
                     4.2.5.    Technological Innovations
           4.3.    Restraints
                     4.3.1.    Variance in Test Results
                     4.3.2.    Availability of Alternative Products
           4.4.    Opportunities
                     4.4.1.    High Growth Prospects in Emerging Countries
           4.5.    Challenges
                     4.5.1.    Reluctance Toward Changing Existing Diagnostic Practices
                     4.5.2.    Interpretation of Results Obtained by OTC Rapid Tests
           4.6.    Regulatory Affairs Analysis
                     4.6.1.    North America
                               4.6.1.1.    U.S.
                               4.6.1.2.    Canada
                     4.6.2.    Europe
                     4.6.3.    Asia-Pacific
                               4.6.3.1.    Japan
                               4.6.3.2.    China
                               4.6.3.3.    Japan
                     4.6.4.    Latin America
                     4.6.5.    Middle East & Africa
           4.7.    Technology Trends
                     4.7.1.    Lateral Flow Assays Containing DNA Nanostructures
                     4.7.2.    Smartphone-based Detection Platforms
                     4.7.3.    Nano-electronic Biosensors in Rapid Diagnostics
           4.8.    Porter's Five Forces Analysis
           4.9.    Pricing Analysis
           4.10.    Parent Market Analysis
                     4.10.1.    Global IVD Market Overview
                     4.10.2.    Global Molecular Diagnostics Market Overview
                     4.10.3.    Global Immunoassay Market Overview
           4.11.    Macroindicators
                     4.11.1.    Diabetes Prevalence, by Region (2021 vs 2045)
                     4.11.2.    Cancer Prevalence, by Region X Cancer Type (2022-2030)
                     4.11.3.    Infectious Disease Outbreaks, by Region (2021-2024)
                     4.11.4.    Global Fertility Rate (2018-2022)
                     4.11.5.    Global Trends in HIV Infections and Mortalities (2023-2030)
           4.12.    Technology Evolution
           4.13.    Value Chain Analysis
           4.14.    Consumer Behavior Analysis
                     4.14.1.    Vendor Selection Criteria
                     4.14.2.    Unmet Needs
                     4.14.3.    Vendor/Brand Analysis
                     4.14.4.    Product/Technology Adoption Trends
    5.    Rapid Diagnostics Market—by Product
           5.1.    Overview
           5.2.    Kits
                     5.2.1.    OTC Kits
                     5.2.2.    Professional Kits
           5.3.    Equipment
    6.    Rapid Diagnostics Market—by Platform
           6.1.    Overview
           6.2.    Immunoassays
                     6.2.1.    Lateral Flow Assays
                     6.2.2.    Serological Assays
                     6.2.3.    Other Immunoassays
           6.3.    Molecular Detection
                     6.3.1.    RT-PCR
                     6.3.2.    Isothermal Nucleic Acid Amplification Technology (INAAT)
           6.4.    Other Rapid Diagnostic Platforms
    7.    Rapid Diagnostics Market, by Application
           7.1.    Overview
           7.2.    Blood Glucose Testing
           7.3.    Cardiac Metabolism Testing
           7.4.    Infectious Disease Testing
                     7.4.1.    Influenza Testing
                     7.4.2.    HIV Testing
                     7.4.3.    Hepatitis Testing
                               7.4.3.1.    Hepatitis B
                               7.4.3.2.    Hepatitis C
                     7.4.4.    Sexually Transmitted Disease (STD) Testing
                     7.4.5.    Healthcare Associated Infection (HAI) Testing
                     7.4.6.    Respiratory Disease Testing
                     7.4.7.    Tropical Disease Testing
                     7.4.8.    Other Infectious Disease Testing
           7.5.    Pregnancy and Fertility Testing
           7.6.    Hematology Testing
           7.7.    Tumor/Cancer Markers Testing
           7.8.    Urinalysis
           7.9.    Cholesterol Testing
           7.10.    Other Applications
    8.    Rapid Diagnostics Market—by Sample Type
           8.1.    Overview
           8.2.    Blood
           8.3.    Saliva, Nasal and Oropharyngeal
           8.4.    Urine
           8.5.    Other Samples
    9.    Rapid Diagnostics Market—by End User
           9.1.    Overview
           9.2.    Hospital & Clinics
           9.3.    Diagnostic Laboratories
           9.4.    Home Care/Self-Testing
           9.5.    Other End Users
    10.    Rapid Diagnostics Market—by Geography
           10.1.    Overview
           10.2.    North America
                     10.2.1.    U.S.
                     10.2.2.    Canada
           10.3.    Europe
                     10.3.1.    Germany
                     10.3.2.    U.K.
                     10.3.3.    France
                     10.3.4.    Italy
                     10.3.5.    Spain
                     10.3.6.    Sweden
                     10.3.7.    Switzerland
                     10.3.8.    Netherlands
                     10.3.9.    Rest of Europe
           10.4.    Asia-Pacific
                     10.4.1.    Japan
                     10.4.2.    China
                     10.4.3.    India
                     10.4.4.    South Korea
                     10.4.5.    Australia
                     10.4.6.    Rest of Asia-Pacific
           10.5.    Latin America
                     10.5.1.    Brazil
                     10.5.2.    Mexico
                     10.5.3.    Rest of Latin America
           10.6.    Middle East & Africa
                     10.6.1.    Saudi Arabia
                     10.6.2.    South Africa
                     10.6.3.    Rest of Middle East & Africa
    11.    Competition Analysis
           11.1.    Overview
           11.2.    Key Growth Strategies
           11.3.    Competitive Benchmarking
           11.4.    Competitive Dashboard
                     11.4.1.    Industry Leaders
                     11.4.2.    Market Differentiators
                     11.4.3.    Vanguards
                     11.4.4.    Emerging Companies
           11.5.    Market Share Analysis, by Key Players (2023)
           11.6.    List of Key Distributors for Rapid Diagnostic Products, by Region
    12.    Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
           12.1.    Abbott Laboratories
           12.2.    Becton, Dickinson and Company (BD)
           12.3.    Bio-Rad Laboratories, Inc.
           12.4.    F. Hoffmann-La Roche Ltd
           12.5.    Acon Laboratories, Inc.
           12.6.    Creative Diagnostics
           12.7.    Danaher Corporation
           12.8.    Thermo Fisher Scientific Inc.
           12.9.    Biomérieux S.A.
           12.10.    Alfa Scientific Designs, Inc.
           12.11.    Btnx Inc.
           12.12.    Meridian Bioscience, Inc.
           12.13.    Trinity Biotech Plc
                       (Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
    13.    Appendix
           13.1.    Available Customization
           13.2.    Related Reports

    List of Tables
    Table 1        Global Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 2        Global Rapid Diagnostic Kits Market, by Type, 2022–2031 (USD Million)
    Table 3        Global Rapid Diagnostic Kits Market, by Country/Region, 2022–2031 (USD Million)
    Table 4        Global Rapid Diagnostic OTC Kits Market, by Country/Region, 2022–2031 (USD Million)
    Table 5        Global Rapid Diagnostic Professional Kits Market, by Country/Region, 2022–2031 (USD Million)
    Table 6        Global Rapid Diagnostic Test Readers/Analyzers Market, by Country/Region, 2022–2031 (USD Million)
    Table 7        Global Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 8        Global Immunoassays Market, by Type, 2022–2031 (USD Million)
    Table 9        Global Immunoassays Market, by Country/Region, 2022–2031 (USD Million)
    Table 10    Global Lateral Flow Assays Market, by Country/Region, 2022–2031 (USD Million)
    Table 11    Global Serological Assays Market, by Country/Region, 2022–2031 (USD Million)
    Table 12    Global Other Immunoassays Market, by Country/Region, 2022–2031 (USD Million)
    Table 13    Global Molecular Detection Market, by Type, 2022–2031 (USD Million)
    Table 14    Global Molecular Detection Market, by Country/Region, 2022–2031 (USD Million)
    Table 15    Global Polymerase Chain Reaction (PCR) Market, by Country/Region, 2022–2031 (USD Million)    
    Table 16    Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market, by Country/Region, 2022–2031 (USD Million)
    Table 17    Global Other Platforms Market, by Country/Region, 2022–2031 (USD Million)
    Table 18    Global Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 19    Global Rapid Diagnostics Market Size for Blood Glucose Testing, by Country/Region, 2022–2031 (USD Million)
    Table 20    Global Rapid Diagnostics Market Size for Cardiac Metabolism Testing, by Country/Region, 2022–2031 (USD Million)
    Table 21    Global Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 22    Global Rapid Diagnostics Market Size for Infectious Disease Testing, by Country/Region, 2022–2031 (USD Million)
    Table 23    Global Rapid Diagnostics Market Size for Influenza Testing, by Country/Region, 2022–2031 (USD Million)
    Table 24    Global Rapid Diagnostics Market Size for HIV Testing, by Country/Region, 2022–2031 (USD Million)
    Table 25    Global Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 26    Global Rapid Diagnostics Market Size for Hepatitis Testing, by Country/Region, 2022–2031 (USD Million)
    Table 27    Global Rapid Diagnostics Market Size for Hepatitis B Testing, by Country/Region, 2022–2031 (USD Million)
    Table 28    Global Rapid Diagnostics Market Size for Hepatitis C Testing, by Country/Region, 2022–2031 (USD Million)
    Table 29    Global Rapid Diagnostics Market Size for Sexually Transmitted Disease (STD) Testing, by Country/Region, 2022–2031 (USD Million)
    Table 30    Global Rapid Diagnostics Market Size for Healthcare Associated Infection (HAI) Testing, by Country/Region, 2022–2031 (USD Million)
    Table 31    Global Rapid Diagnostics Market Size for Respiratory Disease Testing, by Country/Region, 2022–2031 (USD Million)
    Table 32    Global Rapid Diagnostics Market Size for Tropical Disease Testing, by Country/Region, 2022–2031 (USD Million)
    Table 33    Global Rapid Diagnostics Market Size for Other Infectious Disease Testing, by Country/Region, 2022–2031 (USD Million)
    Table 34    Global Rapid Diagnostics Market Size for Pregnancy and Fertility Testing, by Country/Region, 2022–2031 (USD Million)
    Table 35    Global Rapid Diagnostics Market Size for Hematology Testing, by Country/Region, 2022–2031 (USD Million)
    Table 36    Global Rapid Diagnostics Market Size for Tumor/Cancer Markers Testing, by Country/Region, 2022–2031 (USD Million)
    Table 37    Global Rapid Diagnostics Market Size for Urinalysis, by Country/Region, 2022–2031 (USD Million)
    Table 38    Global Rapid Diagnostics Market Size for Cholesterol Testing, by Country/Region, 2022–2031 (USD Million)
    Table 39    Global Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 40    Global Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 41    Global Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 42    Global Rapid Diagnostics Market for blood sample, by Country/Region, 2022–2031 (USD Million)
    Table 43    Global Rapid Diagnostics Market for Saliva, Nasal, and Oropharyngeal Sample, by Country/Region, 2022–2031 (USD Million)
    Table 44    Global Rapid Diagnostics Market for Urine Sample, by Country/Region, 2022–2031 (USD Million)
    Table 45    Global Rapid Diagnostics Market for Other Sample Types, by Country/Region, 2022–2031 (USD Million)
    Table 46    Global Rapid Diagnostics Market, by End User (2022–2031) (USD Million)
    Table 47    Global Rapid Diagnostics Market Size for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
    Table 48    Global Rapid Diagnostics Market Size for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
    Table 49    Global Rapid Diagnostics Market Size for Home Care/Self-Testing, by Country/Region, 2022–2031 (USD Million)
    Table 50    Global Rapid Diagnostics Market Size for Other End Users, by Country/Region, 2022–2031 (USD Million)
    Table 51    Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 52    North America: Rapid Diagnostics Market, by Country, 2022–2031 (USD Million)
    Table 53    North America: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 54    North America: Rapid Diagnostic Kits Market, by Type, 2022–2031 (USD Million)
    Table 55    North America: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 56    North America: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 57    North America: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 58    North America: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 59    North America: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 60    North America: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 61    North America: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 62    North America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 63    U.S.: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 64    U.S.: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 65    U.S.: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 66    U.S.: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 67    U.S.: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 68    U.S.: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 69    U.S.: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 70    U.S.: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 71    U.S.: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 72    U.S.: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 73    Canada: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 74    Canada: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 75    Canada: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 76    Canada: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 77    Canada: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 78    Canada: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 79    Canada: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 80    Canada: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 81    Canada: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 82    Canada: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 83    Europe: Rapid Diagnostics Market, by Country, 2022–2031 (USD Million)
    Table 84    Europe: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 85    Europe: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 86    Europe: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 87    Europe: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 88    Europe: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 89    Europe: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 90    Europe: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 91        Europe: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 92    Europe: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 93    Europe: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 94    Germany: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 95    Germany: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 96    Germany: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 97    Germany: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 98    Germany: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 99    Germany: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 100    Germany: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 101    Germany: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 102    Germany: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 103    Germany: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 104    U.K.: Number of Chlamydia Tests Conducted, 2018–2019
    Table 105    U.K.: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 106    U.K.: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 107    U.K.: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 108    U.K.: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 109    U.K.: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 110    U.K.: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 111        U.K.: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 112    U.K.: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 113    U.K.: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 114    U.K.: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 115    France: Estimated Number of Household Pets, 2017–2019
    Table 116    France: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 117    France: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 118    France: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 119    France: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 120    France: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 121    France: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 122    France: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 123    France: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 124    France: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 125    France: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 126    Italy: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 127    Italy: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 128    Italy: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 129    Italy: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 130    Italy: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 131    Italy: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 132    Italy: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 133    Italy: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 134    Italy: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 135    Italy: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 136    Spain: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 137    Spain: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 138    Spain: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 139    Spain: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 140    Spain: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 141    Spain: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 142    Spain: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 143    Spain: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 144    Spain: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 145    Spain: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 146    Sweden: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 147    Sweden: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 148    Sweden: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 149    Sweden: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 150    Sweden: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 151    Sweden: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 152    Sweden: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 153    Sweden: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 154    Sweden: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 155    Sweden: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 156    Switzerland: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 157    Switzerland: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 158    Switzerland: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 159    Switzerland: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 160    Switzerland: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 161    Switzerland: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 162    Switzerland: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 163    Switzerland: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 164    Switzerland: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 165    Switzerland: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 166    Netherlands: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 167    Netherlands: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 168    Netherlands: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 169    Netherlands: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 170    Netherlands: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 171    Netherlands: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 172    Netherlands: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 173    Netherlands: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 174    Netherlands: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 175    Netherlands: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 176    Rest of Europe: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 177    Rest of Europe: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 178    Rest of Europe: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 179    Rest of Europe: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 180    Rest of Europe: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 181    Rest of Europe: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 182    Rest of Europe: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 183    Rest of Europe: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 184    Rest of Europe: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 185    Rest of Europe: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 186    Asia-Pacific: Rapid Diagnostics Market, by Country, 2022–2031 (USD Million)
    Table 187    Asia-Pacific: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 188    Asia-Pacific: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 189    Asia-Pacific: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 190    Asia-Pacific: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 191    Asia-Pacific: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 192    Asia-Pacific: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 193    Asia-Pacific: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 194    Asia-Pacific: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 195    Asia-Pacific: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 196    Asia-Pacific: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 197    Japan: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 198    Japan: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 199    Japan: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 200    Japan: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 201    Japan: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 202    Japan: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 203    Japan: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 204    Japan: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 205    Japan: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 206    Japan: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 207    China: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 208    China: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 209    China: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 210    China: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 211    China: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 212    China: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 213    China: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 214    China: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 215    China: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 216    China: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 217    India: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 218    India: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 219    India: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 220    India: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 221    India: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 222    India: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 223    India: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 224    India: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 225    India: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 226    India: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 227    South Korea: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 228    South Korea: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 229    South Korea: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 230    South Korea: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 231    South Korea: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 232    South Korea: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 233    South Korea: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 234    South Korea: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 235    South Korea: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 236    Australia: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 237    Australia: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 238    Australia: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 239    Australia: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 240    Australia: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 241    Australia: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 242    Australia: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 243    Australia: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 244    Australia: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 245    Rest of Asia-Pacific: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 246    Rest of Asia-Pacific: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 247    Rest of Asia-Pacific: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 248    Rest of Asia-Pacific: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 249    Rest of Asia-Pacific: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 250    Rest of Asia-Pacific: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 251    Rest of Asia-Pacific: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 252    Rest of Asia-Pacific: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 253    Rest of Asia-Pacific: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 254    Rest of Asia-Pacific: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 255    Latin America: Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 256    Latin America: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 257    Latin America: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 258    Latin America: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 259    Latin America: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 260    Latin America: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 261    Latin America: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 262    Latin America: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 263    Latin America: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 264    Latin America: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 265    Latin America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 266    Brazil: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 267    Brazil: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 268    Brazil: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 269    Brazil: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 270    Brazil: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 271    Brazil: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 272    Brazil: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 273    Brazil: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 274    Brazil: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 275    Brazil: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 276    Mexico: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 277    Mexico: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 278    Mexico: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 279    Mexico: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 280    Mexico: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 281    Mexico: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 282    Mexico: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 283    Mexico: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 284    Mexico: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 285    Latin America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 286    Rest of Latin America: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 287    Rest of Latin America: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 288    Rest of Latin America: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 289    Rest of Latin America: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 290    Rest of Latin America: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 291    Rest of Latin America: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 292    Rest of Latin America: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 293    Rest of Latin America: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 294    Rest of Latin America: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 295    Rest of Latin America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 296    Middle East & Africa: Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
    Table 297    Middle East & Africa: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 298    Middle East & Africa: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 299    Middle East & Africa: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 300    Middle East & Africa: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 301    Middle East & Africa: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 302    Middle East & Africa: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 303    Middle East & Africa: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 304    Middle East & Africa: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 305    Middle East & Africa: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 306    Middle East & Africa: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 307    Saudi Arabia: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 308    Saudi Arabia: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 309    Saudi Arabia: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 310    Saudi Arabia: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 311    Saudi Arabia: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 312    Saudi Arabia: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 313    Saudi Arabia: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 314    Saudi Arabia: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 315    Saudi Arabia: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 316    Saudi Arabia: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 317    South Africa: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 318    South Africa: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 319    South Africa: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 320    South Africa: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 321    South Africa: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 322    South Africa: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 323    South Africa: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 324    South Africa: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 325    South Africa: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 326    South Africa: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 327    Rest of Middle East & Africa: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
    Table 328    Rest of Middle East & Africa: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
    Table 329    Rest of Middle East & Africa: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
    Table 330    Rest of Middle East & Africa: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 331    Rest of Middle East & Africa: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
    Table 332    Rest of Middle East & Africa: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
    Table 333    Rest of Middle East & Africa: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
    Table 334    Rest of Middle East & Africa: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
    Table 335    Rest of Middle East & Africa: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
    Table 336    Rest of Middle East & Africa: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
    Table 337    Recent Developments, by Company, 2021-2024


    List of Figures
    Figure 1    Research Process
    Figure 2    Secondary Sources Referenced for This Study
    Figure 3    Primary Research Techniques
    Figure 4    Key Executives Interviewed
    Figure 5    Breakdown of Primary Interviews (Supply Side & Demand Side)
    Figure 6    Market Sizing and Growth Forecast Approach
    Figure 7    Global Rapid Diagnostics Market Size, by Product, 2024 Vs. 2031 (USD Million)
    Figure 8    Global Rapid Diagnostics Market Size, by Platform, 2024 Vs. 2031 (USD Million)
    Figure 9    Global Rapid Diagnostics Market Size, by Application, 2024 Vs. 2031 (USD Million)
    Figure 10    Global Rapid Diagnostics Market Size, by Sample Type, 2024 Vs. 2031 (USD Million)
    Figure 11    Global Rapid Diagnostics Market Size, by End User, 2024 Vs. 2031 (USD Million)
    Figure 12    Global Rapid Diagnostics Market, by Region
    Figure 13    Impact Analysis of Market Dynamics 
    Figure 14    Global Rapid Diagnostics Market Size, by Product, 2024 Vs. 2031 (USD Million)
    Figure 15    Global Rapid Diagnostics Market Size, by Platform, 2024 Vs. 2031 (USD Million)
    Figure 16    Global Rapid Diagnostics Market Size, by Application, 2024 Vs. 2031 (USD Million)
    Figure 17    Global Rapid Diagnostics Market Size, by Sample Type, 2024 Vs. 2031 (USD Million)
    Figure 18    Global Rapid Diagnostics Market Size, by End User, 2024 Vs. 2031 (USD Million)
    Figure 19    North America: Rapid Diagnostics Market Snapshot
    Figure 20    Europe: Rapid Diagnostics Market Snapshot
    Figure 21    Asia-Pacific: Rapid Diagnostics Market Snapshot
    Figure 22    Latin America: Rapid Diagnostics Market Snapshot
    Figure 23    Middle East & Africa: Rapid Diagnostics Market Snapshot
    Figure 24    Key Growth Strategies Adopted by Leading Players (2021–2024)
    Figure 25    Rapid Diagnostics Market: Competitive Benchmarking, by Application
    Figure 26    Rapid Diagnostics Market: Competitive Benchmarking, by Region
    Figure 27    Competitive Dashboard Rapid Diagnostics Market
    Figure 28    Global Rapid Diagnostics Market Share/Market Ranking Analysis, by Key Players, 2023
    Figure 29    Vendor Selection Criteria
    Figure 30    Vendor/Brand Analysis
    Figure 31    Abbott Laboratories: Financial Overview (2023)
    Figure 32    Becton, Dickinson and Company: Financial Overview (2023)
    Figure 33    Bio-Rad Laboratories, Inc.: Financial Overview (2023)
    Figure 34    F. Hoffmann-La Roche Ltd: Financial Overview (2023)
    Figure 35    Danaher Corporation: Financial Overview (2023)
    Figure 36    Thermo Fisher Scientific Inc.: Financial Overview (2023)
    Figure 37    Biomérieux S.A.: Financial Overview (2023)
    Figure 38    Meridian Bioscience, Inc.: Financial Overview (2023)
    Figure 39    Trinity Biotech Plc: Financial Overview (2023)

    Enquire
    Check Discount
    Author Name:

    Madhura Pawar, Pranjali Takale, Mahesh Khillari

    Related Tag: Rapid Diagnostics Market In vitro Diagnostic Immunoassays PCR Blood Glucose Testing Infectious Diseases Healthcare Associated Infection Pregnancy Testing Hematology Test Cancer Markers Drugs of Abuse Cholesterol Testing Rapid PCR Tests
    In Vitro Diagnostics
    Healthcare
    Rapid Diagnostics Market is expected to reach $22.65 billion by 2031 from an estimated $14.57 billion in 2024, at a CAGR of 6.5% during the forecast period from 2024 to 2031.
     
    The growth in rapid diagnostics market is mainly attributed to growing demand for POC diagnostics, rising prevalence of chronic diseases coupled with aging population, increasing demand for rapid decision making in emergency departments, and emerging technological innovations. However, variance occurring in test results is expected to hinder the growth of the market.

    Here are the top 10 companies operating in the Rapid Diagnostics Market

    Abbott Laboratories (U.S.)

    Abbott Laboratories develops, manufactures, and markets a broad and diversified range of healthcare products. The company operates through four reportable business segments, namely, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company operates in the rapid diagnostics market through its Diagnostics business segment. The Diagnostic Products segment offers a broad line of diagnostic systems and tests manufactured, marketed, and sold to blood banks, hospitals, commercial laboratories, clinics, physicians’ offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic firms globally.

    Abbott has its presence across various countries like Germany, Japan, India, Switzerland, Russia, France, Brazil, Italy, the U.K., the U.S., the Netherlands, Colombia, and Vietnam. The company operates through its 92 manufacturing facilities across the globe, of which 23 are for diagnostic product manufacturing. The company has its R&D centers in the U.S., Canada, Germany, Norway, and the U.K.

    Becton, Dickinson and Company (U.S.)

    Becton, Dickinson and Company (BD) is a medical technology firm engaged in developing, manufacturing, and selling a broad line of medical devices, supplies, laboratory equipment, and diagnostic products. The company offers its products to healthcare institutions, life science researchers, physicians, clinics, diagnostic laboratories, and the pharmaceutical industry. BD operates through three reportable business segments, namely, BD Medical, BD Life Sciences, and BD Interventional. The BD Life Sciences segment offers products for the safe collection and transportation of diagnostic specimens and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections, and cancers. In addition, this segment also produces research and clinical tools that promote the study of cells, and the components of cells, to acquire a better understanding of normal and disease processes. The BD Life Sciences segment consists of two organizational units: Integrated Diagnostic Solutions and Biosciences. The company operates in the rapid diagnostics market through Integrated Diagnostic Solutions, an organizational unit of the BD Life Sciences business segment.

    The company has its manufacturing facilities outside the U.S. in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain, and the U.K. The subsidiaries of the company operating in the rapid diagnostics market include Becton Dickinson Canada Inc., Becton Dickinson GmbH (Germany), BD Rapid Diagnostic (Suzhou) Co., Ltd. (China), Becton Dickinson Asia Limited (Hong Kong), Becton, Dickinson B.V. (Netherlands), and Becton Dickinson India Private Limited.

    Bio-Rad Laboratories, Inc. (U.S.)

    Bio-Rad is a manufacturer and distributor of life science research and clinical diagnostics products and systems broadly used by life science research, healthcare, and analytical chemistry, among other markets, to separate complex chemical and biological materials and identify, analyze, and purify components. The company has two reportable business segments, namely, Life Science and Clinical Diagnostics.

    The company operates in the rapid diagnostics market through its Clinical Diagnostics business segment. The segment designs, manufactures, and sells test systems, informatics systems, test kits, and specialized quality controls and serves hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories as their end customer.

    Bio-Rad has its presence in over 36 countries outside the U.S. through subsidiaries. The company’s principal manufacturing and research sites are in countries namely: the U.S., Singapore, the U.K., France, Belgium, Switzerland, and Germany.

    Hoffmann-La Roche Ltd. (Switzerland)

    Hoffmann-La Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable business divisions, namely, Pharmaceuticals and Diagnostics. The company operates in the rapid diagnostics market through its Diagnostics division. The Diagnostics division develops a wide range of diagnostic products and solutions that include in vitro diagnostics solutions, molecular diagnostics, clinical chemistry & immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision support solutions.

    Roche has its presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. The company has subsidiaries across the globe to fulfill its production and sales needs. The subsidiaries of the company operating in the rapid diagnostics market include Genentech (U.S.), Roche Diagnostics (U.S.), Roche Diagnostics GmbH (Germany), Roche Diagnostics (Shanghai) Ltd. (China), Roche Diagnostics (Suzhou) Limited (China), and Roche Diagnostics K.K (Japan).

    ACON Laboratories, Inc. (U.S.)

    Founded in 1996 and headquartered in California, U.S., ACON manufactures and markets rapid diagnostics and healthcare products worldwide. Some of the brands offered by the company include On Call, Mission, HealthyMe, ACON, Flowflex, Distinct, Foresights, Promotor, and Centrivet. The U.S. office is the center of strategic management, business development, administration, and research & development. The company has a presence in over 130 countries with ISO13485: 2016 certified manufacturing facility in Hangzhou, China.

    Creative Diagnostics (U.S.)

    Headquartered in New York, U.S., Creative Diagnostics manufactures and markets antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. The company also offers biologic contract R&D and manufacturing services and GMP biologics manufacturing to diagnostic manufacturers and biopharmaceutical firms. In addition, the company also assists its clients in developing, manufacturing, and commercializing point of care devices such as lateral flow, flow through, and ELISA assays. With a strong distribution network, the company has its presence in over 30 countries worldwide.

    Danaher Corporation (U.S.)

    Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through three reportable business segments, namely, Life Sciences, Diagnostics, and Environmental & Applied Solutions.

    Beckman Coulter Inc. (U.S.), Cepheid (U.S.), HemoCue AB (Sweden), and Radiometer Medical ApS (Denmark) are the subsidiaries of the company providing rapid diagnostic kits. These subsidiaries operate in the rapid diagnostics market through its Diagnostics business segment. The Diagnostics business segment offers a wide range of analytical instruments, reagents, consumables, software, and services to diagnose disease and make crucial treatment decisions and serves hospitals, physicians’ offices, reference laboratories, and other critical care settings.

    The company has a presence in over 60 countries. The non-U.S. countries in which Danaher has a significant presence include China, Denmark, Germany, Singapore, Sweden, Switzerland, and the U.K. The manufacturing facilities of the Diagnostics business segment are located in North America, Europe, Asia, and Australia.

    Thermo Fisher Scientific Inc. (U.S.)

    Thermo Fisher offers a wide range of healthcare technologies, software, and services. The company operates through four reportable business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company operates in the rapid diagnostics market through its Life Sciences Solutions and Specialty Diagnostics business segments. The Life Sciences Solutions business segment offers a wide range of reagents, instruments, and consumables used in biological and medical research, the discovery and production of new drugs and vaccines, and the diagnosis of infection and disease. The Specialty Diagnostics business segment offers a broad range of diagnostic test kits, reagents, instruments, culture media, and associated products used in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.

    Thermo Fisher has its operations and a presence in approximately 50 countries outside the U.S. The company has major manufacturing and distribution facilities worldwide, including in the U.S., Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, and the U.K. The company serves more than 400,000 end customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research & academic institutions, government firms, and environmental, industrial quality, and process control settings.

    bioMérieux S.A. (France)

    bioMérieux develops, manufactures, and markets in vitro diagnostic solutions. The company operates through two business segments, namely, Clinical Applications and Industrial Applications. The company operates in the rapid diagnostics market through its Clinical Applications segment. The Clinical Applications segment provides in-vitro diagnostic solutions that help doctors and healthcare workers to determine the source of disease. This segment is further categorized into microbiology, immunoassays, and molecular biology.

    bioMérieux has its direct presence in 44 countries, and with a strong distribution network, the company serves more than 160 countries globally. The company has manufacturing sites for clinical solutions in the U.S., Canada, Japan, Brazil, and Australia.

    Alfa Scientific Designs, Inc. (U.S.)

    Founded in 1996 and headquartered in California, U.S., Alfa Scientific manufactures and markets rapid POC diagnostics devices used for screening drugs of abuse, fertility hormones, infectious diseases, cardiac and cancer markers, and other diagnostic areas. Alfa also offers product development and manufacturing services that include latex, lateral flow, fluorescent methodologies, OEM services, custom assay/device assembly, and packing with client-specific labeling. The company has also been granted 28 patents for its products and technologies.

    Popular Mentions: BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland)

     

      This website is secure and we do not share your personal information with any third party. privacy policy
      You will also receive a PDF copy of this sample in your mailbox.

      Proudly Partnering With Enterprises Around the Globe

      Accenture Amazon BCG-Corporate BioRad Boehringer-Ingelheim Deloitte Fujifilm Intel PEPSICO Samsung Olympus McKinsey LG-Chem Rosetta-Stone tata-consultancy-services SK Kao IQVIA Vemag Canada Genscript Grupo-Vilaseca HEC Highland-Metals-Inc
      Related Tag: Rapid Diagnostics Market In vitro Diagnostic Immunoassays PCR Blood Glucose Testing Infectious Diseases Healthcare Associated Infection Pregnancy Testing Hematology Test Cancer Markers Drugs of Abuse Cholesterol Testing Rapid PCR Tests
      Request Sample
      Customize My Report
      Quick Contact
      Chat on Whatsapp
      Linkdin
      Whatsapp
      Feed
      Related Reports
      Latin America Molecular Diagnostics Market - Opportunity Analysis and Industry Forecasts (2025-2032)

         Published Date: Jan-2025

      Livestock Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)

         Published Date: May-2024

      Tuberculosis Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2025-2032)

         Published Date: May-2024

      Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)

         Published Date: Feb-2024

      Veterinary Rapid Diagnostic Tests Market - Global Opportunity Analysis And Industry Forecast (2023-2030)

         Published Date: Apr-2023

      Table Of Content
      Download Free Sample Report
      Meticulous Research
      US
      +1 646-781-8004
      Meticulous Research
      Europe
      +44-203-868-8738
      Meticulous Research
      APAC
      +91-744-778-0008